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OBJECTIVES This study assessed the use of adenosine triphosphate (ATP) in the noninvasive diagnosis of
concealed accessory pathway (AP) and dual atrioventricular (AV) node physiology in patients
with inducible AV reentrant tachycardia (AVRT).
BACKGROUND Administration of ATP during sinus rhythm identifies dual AV node physiology in 76% of
patients with inducible sustained slow/fast AV nodal reentry tachycardia (AVNRT).
METHODS Incremental doses of ATP were intravenously administered during sinus rhythm to 34
patients with inducible sustained AVRT involving a concealed AP and to 27 control patients
without AP or dual AV node physiology. One study group patient could not complete the
study and was excluded from analysis.
RESULTS The AV reentrant echo beats (AVRE), or AVRT, suggestive of the presence of concealed
AP, were observed after ATP administration in 24 (73%) study patients and in none of the
control group. Electrocardiographic signs suggestive of dual AV node physiology were
observed after ATP administration in 7 (21%) study patients and in none of the control
group. Most instances of AVRE/AVRT were preceded by a slight increase (,50 ms) in PR
interval. In 8 of 9 patients tested, neither AVRE nor AVRT was no longer observed following
ATP administration after successful radiofrequency ablation of the AP. In the remaining
patient, a different AVRE due to the presence of an additional AP was observed.
CONCLUSIONS Administration of ATP during sinus rhythm may be a useful bedside test for identifying
patients with concealed AP who are prone to AVRT and those with associated dual AV node
pathways. (J Am Coll Cardiol 2000;36:803–10) © 2000 by the American College of
Cardiology
Regular, paroxysmal supraventricular tachycardia (PSVT)
occurring in patients without antegradely conducting acces-
sory pathways (AP) is due to atrioventricular nodal reentry
tachycardia (AVNRT) in 51% of cases, atrioventricular
reentrant tachycardia (AVRT) in 34% of cases, and to
various mechanisms in the remaining 15% (1). We recently
showed that administration of adenosine-59-triphosphate
(ATP) during sinus rhythm identifies dual atrioventricular
(AV) node physiology in 76% of patients with inducible
sustained slow/fast AVNRT (2). Because the AV nodal
conduction delay caused by the administration of ATP
during sinus rhythm may allow the occurrence of AV
reentrant orthodromic echo beats (AVRE) or AVRT in
patients with concealed AP, we sought to assess the use of
ATP in the noninvasive diagnosis of such APs. We also
analyzed the incidence of dual AV nodal physiology using
ATP test in these patients.
METHODS
Patient population. The study group consisted of consec-
utive patients from Tel-Aviv and Sheba medical centers
who had suspected and subsequently proven inducible
sustained AVRT at electrophysiologic study performed
during the course of a radiofrequency ablation procedure.
All patients had sustained AVRT induced before or after
the intravenous (IV) administration of isoproterenol and
were evaluated in the absence of antiarrhythmic drug
therapy. At the time of electrophysiologic study no patient
had evidence of antegrade conduction over an AP using
appropriate atrial pacing techniques.
A control group included patients who had no electro-
physiologic evidence of AP or dual AV node physiology nor
inducible tachycardia on isoproterenol after they underwent
ablation of their slow pathway with radiofrequency energy.
These patients were also part of another study that evaluated
the effects of radiofrequency ablation of the slow pathway on
ATP-induced dual AV node physiology (3). None of the
patients had a history of asthma, a contraindication to ATP
administration, and none were treated with antiarrhythmic
drugs or with drugs known to interfere with ATP metab-
olism (aminophylline, dipyridamole, benzodiazepines).
ATP test. The ATP test was performed after the patients
gave informed consent. The effects of ATP were evaluated
during sinus rhythm. The ATP (Striadyne, Wyeth Labo-
ratories, France) was injected through a right antecubital
vein as a rapid bolus followed by a 20-ml flush of normal
saline. The initial dose of ATP was 10 mg. Repeated doses
(with 10-mg increments) were given at 1–2 min intervals
after return of sinus rate to control, until one of the
following prospectively defined end points was observed: 1)
occurrence of $1 AVRE (see following text) or 2) second-
degree or third-degree AV block. The test was discontinued
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if severe clinical intolerance or sinus bradycardia causing
.3-s pause occurred when a maximal dose of 60 mg ATP
was given. The observation of electrocardiographic (ECG)
signs of dual AV node physiology during ATP adminis-
tration (see following text) was also noted but was not
considered a study end point.
To avoid possible catheter-induced trauma to APs (4) or
catheter-induced arrhythmias, the baseline ATP test was
performed in all study patients prior to placement of any
electrode catheter in the cardiac chambers. The ATP test
was repeated after radiofrequency ablation of the accessory
pathway in nine patients who had ECG signs suggesting the
presence of a concealed AP at initial ATP test. In these nine
patients, the ATP test was performed while electrode
catheters were in the cardiac chambers.
ECG definitions during ATP test. The ECG signs sug-
gestive of the presence of a concealed AP during ATP
administration were considered to be present when at least
one of the following events was observed: 1) an echo beat
was present with a retrograde P wave that had a morphology
and a RP relationship similar to that present during the
AVRT induced at subsequent electrophysiologic study, and
2) an AVRT (sustained or nonsustained) was initiated. For
study analysis, at least two consecutive AVREs were con-
sidered as AVRT. A sustained tachycardia was defined as a
tachycardia lasting $30 s.
Electrocardiographic signs of dual AV node physiology
during ATP administration (2) were considered to be
present when at least one of the following events was
observed: 1) PR interval increased or decreased by $50 ms
between two consecutive sinus beats and 2) an AV nodal
echo beat or AVNRT developed. All these criteria were
based on the analysis of simultaneous 12-lead surface ECG
only. In our previous study (2), we found an excellent
correlation between the results of surface ECG recordings
with those of intracardiac recordings.
The number of episodes of AVRE and AVRT as well as
the mode of initiation of the first-occurring AVRE or
AVRT were also analyzed.
Electrophysiologic study. After obtaining patient in-
formed consent, the electrophysiologic study was performed
using electrode catheters (Bard) placed in the His bundle
area, right ventricular apex, right atrium, and in most
instances the coronary sinus, as previously described (5).
Briefly, the baseline electrophysiologic study included 1)
delivery of one to three extrastimuli during atrial or ventric-
ular pacing at a cycle length of 600 ms until the atrial or
ventricular refractory period was reached; and 2) incremen-
tal atrial or ventricular pacing until antegrade or retrograde
block in the AV node or AP, respectively, was achieved. If
sustained AVRT was not induced using this protocol,
isoproterenol was administered at incremental dosage until
the basic sinus rhythm increased by at least 20% and the
stimulation protocol was repeated. Diagnosis of the pres-
ence, involvement, and location of a concealed AP was
made according to standard criteria including the delivery of
single ventricular extrastimulation during tachycardia at the
time the His bundle was refractory (1).
“Dual AV node physiology” was defined as a $50-ms
increment in A2H2 value following a 10-ms decrement in
the A1–A2 interval with single atrial extrastimulation (A1)
administered during atrial pacing at a basic cycle length
A1–A1 of 600 ms or a $50-ms increment in A-H value in
consecutive beats following a #10-ms decrement in pacing
cycle length during incremental atrial pacing (1,2).
Statistics. Data were expressed as mean 6 SD. Statistical
analysis was performed using the chi-square test. A value of
p , 0.05 was considered statistically significant.
RESULTS
Patient characteristics. Thirty-four patients (Tel-Aviv
Medical Center, n 5 24; Sheba Medical Center, n 5 10)
with inducible AVRT underwent ATP test during sinus
rhythm (Table 1). One patient (Patient 10) who did not
reach a study end point with 40 mg ATP and who refused
the administration of a higher dose was excluded from
further analysis. The remaining 33 patients completed the
ATP test and constituted the study group. There were 26
men and 7 women, aged 36.9 6 17.1 years old. Thirty-two
patients had sustained AVRT of the common type (RP ,
PR); in these patients, AVRT was inducible without iso-
proterenol. The remaining patient (Patient 6) had the long
RP type of AVRT (RP . PR) that was inducible only
during isoproterenol infusion. None of the study group
patients had organic heart disease. The control group
comprised 27 patients (13 women and 14 men, mean age
51 6 18 years), none of whom had organic heart disease.
Results of ATP test in the study group. OCCURRENCE OF
AVRE OR AVRT. Of the 33 study group patients, 24 (73%)
developed AVRE or AVRT following the administration of
10 to 30 (mean 18.3 6 6.9) mg ATP (Table 1) (Figs. 1–4).
The doses of ATP required to demonstrate the presence of
a concealed AP were 10, 20, and .20 mg in 10 (42%), 8
(33%), and 6 (25%) of the 24 patients. The remaining 9
(27%) patients developed transient second- or third-degree
AV block, without AVRE or AVRT, following the admin-
istration of 10 mg to 40 mg (mean 17 6 8) ATP.
A total of 52 AVREs (1 to 7 per patient, mean 2.5 6 1.3)
were observed in 21 (64%) of the 33 study patients (Figs.
1–3). Seven patients had 1 AVRE, 6 patients had 2 AVREs,
Abbreviations and Acronyms
AP 5 accessory pathway
ATP 5 adenosine triphosphate
AV 5 atrioventricular
AVNRT 5 atrioventricular nodal reentry tachycardia
AVRE 5 atrioventricular reentrant echo beats
AVRT 5 atrioventricular reentrant tachycardia
ECG 5 electrocardiographic
PSVT 5 paroxysmal supraventricular tachycardia
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and the remaining 8 patients had 3 to 7 AVREs. The first
AVRE occurred 10 to 23 s (mean 16 6 3.5 s) following the
ATP bolus. The first AVRE occurred following a slight
increase (,50 ms) in PR interval between two consecutive
beats in 13 patients associated with a slight increase,
decrease, or no change in the preceding sinus cycle length in
4, 2, and 7 patients, respectively (Fig. 3). In six patients, the
first AVRE occurred following a sudden increase ($50 ms)
in PR interval between two consecutive beats (dual AV node
physiology) associated with a slight increase, decrease, or no
change in the preceding sinus cycle length in 1, 1, and 4
patients, respectively (Figs. 1 and 2). In the patient with
long RP tachycardia (Patient 6), the first AVRE followed
no obvious change in the PR interval or the preceding sinus
cycle length. Finally, in one patient (Patient 32), the first
AVRE followed an atrial extrasystole occurring during
stable sinus rhythm.
The AVRT (1 to 2 episodes) was observed following
ATP administration in 10 (30%) of 33 study patients (Figs.
2 and 4). Seven of the 10 patients with AVRT also
demonstrated $1 AVRE, which invariably occurred before
AVRT (Fig. 2). AVRT was sustained in five patients and
nonsustained in five. Also, AVRT occurred 10 to 45 s (19 6
10 s) following the ATP bolus. Initiation of the first AVRT
after ATP administration followed a slight (,50 ms) PR
prolongation in five patients (during undisturbed sinus
rhythm in three patients) or was triggered by atrial extra-
systoles in three patients (Figs. 2 and 4). AVRT started
during stable sinus rhythm without any measurable change
in PR interval in the patient with long RP tachycardia
(Patient 6). In the remaining patient (Patient 25), the mode
of initiation of the AVRT could not be determined.
OCCURRENCE OF DUAL AV NODE PHYSIOLOGY. Electrocar-
diographic signs suggestive of dual AV node physiology
following ATP test (2) were observed in seven (21%) of the
Table 1. Patient Characteristics and Results of ATP Test and Electrophysiologic Study
Pt S/A AP Site
ATP Test Results
EPS-DAVNP
AVRE AVRT
DAVNPN Mechanism N(d) Mechanism
1 M 61 LFW 0 0 2 1
2 F 50 RPS 1 CL3 PR1 1 (S) CL3 1APC 2 2
3 M 21 LFW 0 0 2 2
4 M 21 RAS 1 CL3 PR1 1 (NS) CL3 PR1 2 2
5 F 68 LFW 0 0 2 2
6 M 21 RPS 1 CL3 PR3 1 (NS) CL3 PR3 2 2
7 M 59 RAS 3 CL2 PR1 1 (S) CL? PR1 2 2
8 F 72 LFW 0 0 2 2
9 M 22 LFW 1 CL2 DAVNP 0 1 1
10 M 23 LFW Excluded due to patient intolerance without reaching end point with ATP 40 mg 2
11 M 21 LFW 3 CL3 DAVNP 0 1 1
12 M 63 LFW 0 0 2 2
13 M 22 LFW 2 CL1 PR1 0 2 2
14 M 60 LFW 0 0 1 1
15 M 55 LFW 1 CL3 PR1 0 2 2
16 M 22 LFW 0 0 2 2
17 M 19 RPS 3 CL1 DAVNP 0 1 1
18 F 48 RFW 0 2 (NS) CL3 PR1 2 2
19 M 27 LFW 2 CL3 DAVNP 0 1 1
20 M 16 RAS 3 CL1 PR1 0 2 2
21 F 20 RFW 2 CL1 PR1 1 (NS) CL2 PR1 2 2
22 F 34 LFW 1 CL1 DAVNP 1 (NS) CL3
2APC’S
1 1
23 M 53 LFW 2 CL3 PR1 0 2 1
24 M 56 PS 5 CL3 PR1 0 2 2
25 M 44 RAS 2 CL3 PR1 2 (S) Undetermined 2 2
26 M 17 PS 6 CL2 PR1 0 2 2
27 M 25 LFW 0 1 (S) CL3 PR1 2 2
28 M 18 LFW 3 CL3 PR1 0 2 2
29 M 39 LFW 0 0 2 2
30 M 51 RAS 0 0 2 2
31 F 15 LFW 0 1 (S) CL3 1APC 2 2
32 M 57 RAS 7 CL3 1APC 0 2 2
33 M 24 LFW 2 CL1 PR1 0 2 2
34 M 18 PS 1 CL3 DAVNP 0 1 1
A 5 age; AP 5 accessory pathway; APC5 atrial premature complex; AVRE 5 atrioventricular reentrant echo beat; AVRT 5 atrioventricular reentrant tachycardia; CL 5 sinus
cycle length; (d) 5 duration; DAVNP 5 dual atrioventricular node physiology; EPS 5 electrophysiologic study; F 5 female; LFW 5 left free wall; M 5 male; N 5 number;
(NS) 5 nonsustained; PR 5 PR interval; PS 5 posteroseptal; Pt 5 patient; RAS 5 right anteroseptal; RFW 5 right free wall; S 5 sex; (S) 5 sustained.
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study patients (Figs. 1 and 2). Of these seven patients, six
also exhibited AVRE (Patients 9, 11, 17, 19, 22, 34). In five
of these patients, all instances of AVRE were preceded by
dual AV node physiology; in the remaining patient (Patient
11) who exhibited three AVREs, only two of these echo
beats followed the occurrence of dual AV node physiology
(Fig. 1). None of the patients with dual AV node physiology
exhibited AV nodal echo beats during ATP test.
ADVERSE EFFECTS. One patient (Patient 5) had an asymp-
tomatic 4-s sinus pause with 10 mg ATP while reaching the
study end point of second-degree AV block. Another
patient (Patient 12) developed transient atrial fibrillation a
few seconds after reaching the study end point of second-
degree AV block. Besides the well-known mild and tran-
sient side effects related to ATP administration (flushing),
no other significant adverse effects were observed.
ATP TEST AFTER RADIOFREQUENCY ABLATION. The radio-
frequency ablation procedure was successful in 30 (91%)
study patients and failed in 3 (Patients 23, 24, 31). In 8
patients (Patients 15, 17, 20, 26–28, 32, 34) who had
AVRE or AVRT at baseline ATP test and underwent
successful radiofrequency ablation of the AP, repeat ATP
test using the same dose of ATP did not show AVRE or
AVRT (Fig. 4). In one patient (Patient 33) who had AVRE
at baseline ATP test, an AVRT involving a concealed left
lateral AP was induced that had retrograde P waves with
morphology and RP relationship (RP 5 0.12 s) similar to
that present during AVRE. After successful radiofrequency
ablation of this pathway, repeat ATP test induced an atrial
activity following a QRS complex (RP 5 0.15 s) suspected
to be either an atrial extrasystole or AVRE. This P wave was
slightly different in morphology to that of the AVRE
observed at baseline ATP test (more negative axis).
At repeat electrophysiologic study, a sustained AVRT
was induced that involved another concealed AP located in
the left posterior area about 2 cm from the first ablated
pathway. The morphology of the AVRE and the RP
relationship were identical to that of the retrograde P wave
during AVRT. This AVRE was no longer observed follow-
ing ATP after successful radiofrequency ablation of the
posterior AP.
Results of ATP test in the control group. Of the 27
control patients, none exhibited AVRE, AVRT, or dual AV
node physiology following the administration of 10 to 40
(mean 17 6 9) mg ATP. In addition, none exhibited any
atrial premature beat. All patients developed transient
second- or third-degree AV block following ATP admin-
istration.
Electrophysiologic data. Electrophysiologic evidence of
dual AV node physiology was observed in 9 (27%) of 33
study patients (Table 1). In three of these patients (Patients
1, 9, 34), two tachycardias with different rates could be
documented during AVRT, reflecting antegrade AV con-
duction over either the slow or the fast pathway. Of these
nine patients with electrophysiologic evidence of dual AV
node physiology, seven (78%) exhibited ECG signs of dual
Figure 1. Patient 11. Initiation of AV reentrant echo beats following the administration of 20 mg ATP during sinus rhythm in a patient with a concealed left
free wall AP and electrophysiologic evidence of antegrade dual AV node physiology. Note that the first two echo beats follow a sudden jump in PR interval of
70 ms (dual AV node physiology) while the prolongation in PR interval preceding the third echo beat is of 40 ms only. Also note that the sinus cycle length
preceding the first echo beat is regular at 710 ms.
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AV node physiology by ATP test. None of the patients with
electrophysiologic evidence of dual AV node physiology had
inducible AV nodal echoes. Of the nine patients with dual
AV nodal physiology at electrophysiologic study, seven
(78%) had AVRE or AVRT at ATP test; of the 18 patients
without dual AV nodal physiology, 13 (72%) had AVRE or
AVRT at ATP test (p 5 NS).
The location of the APs in the study patients was as
follows: left free wall in 19 patients, posteroseptal in 6
patients, right anteroseptal in 6 patients, and right free wall
in 2 patients. Electrophysiologic evidence of dual AV node
physiology was much more frequently observed in patients
with left free wall APs (7 of 19; 39%) than in patients with
non-left free wall APs (2 of 14; 14%) but the difference was
not statistically significant (p . 0.1). The presence of
AVRE or AVRT following ATP administration was ob-
served in 11 (58%) of the 19 patients with left free wall
pathways and in 13 of 14 (93%) patients with non-left free
wall pathways (p , 0.05).
DISCUSSION
Main findings. In the present study, we found that the
administration of ATP during sinus rhythm revealed signs
suggestive of the presence of a concealed AP in a high
percentage (73%) of patients with inducible sustained
AVRT but in no patient from the control group. Thus,
observation of AVRE or AVRT after ATP injection cor-
related with the induction of AVRT during electrophysi-
ologic study with a sensitivity of 73%, a specificity of 100%,
and a positive and negative predictive value of 100% and
100%, respectively. In addition, the administration of ATP
during sinus rhythm enabled the diagnosis of associated
dual AV node pathways in seven (21%) of the study patients
but none of the control group subjects.
Use of ATP in the diagnosis of concealed AP. Admin-
istration of ATP during sinus rhythm has already been
successfully used to establish the diagnosis of Wolff-
Parkinson-White syndrome in patients with a minor degree
of preexcitation and to assess the results of an ajmaline test
in patients with preexcitation (6). Our study is the first that
shows that ATP can also be successfully used for the
noninvasive diagnosis of a concealed AP in patients with
PSVT. Similar observations were recently made by other
investigators (7) using a fixed dose (12 mg) of adenosine at
the completion of a diagnostic electrophysiologic study. In
that study, AVRE were observed in 10 (80%) of 12 patients,
Figure 2. Patient 22. Initiation of both AV reentrant beat and sustained AV reentrant tachycardia following the administration of 30 mg ATP in a patient
with a concealed left free wall AP and electrophysiologic evidence of antegrade dual AV node physiology. The AV reentrant echo beat occurs 16 s after
the ATP bolus during stable sinus rhythm (740 ms) while AV reentrant tachycardia triggered by atrial premature beats occurs 6 s later. Note that a PR
jump of 80 ms is present on the beat associated with the AV reentrant echo beat.
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including 2 patients who subsequently developed AVRT.
Interestingly, the incidence of AVRE/AVRT found in that
study (80%) was similar to that found in our study (73%),
despite the fact that the dose of adenosine used in the
former study (12 mg) was equivalent to about 23 mg ATP
(taking into account the different molecular weights of ATP
and adenosine). Indeed, our study showed that doses of
10 mg ATP (equivalent to about 5.3 mg adenosine) were
sufficient to reveal AVRE/AVRT in 42% of our patients. In
theory, the use of high doses of adenosine or ATP could
result in complete AV nodal block, preventing the initiation
of AVRE.
Mechanism of AVRE and AVRT during ATP test. Our
study gives further insight into the mechanism of occurrence
of AVRE and AVRT during ATP test. A slight increase in
PR interval associated with no change in preceding sinus
cycle length represented the most frequent mechanism in
patients without dual AV node physiology, whereas a
marked jump in PR interval preceded the initiation of
AVRE or AVRT in patients with dual AV node physiology.
In the patient with long RP tachycardia, induction of
AVRE and AVRT by ATP without significant change in
PP and PR interval may be explained by either a small and
unrecognized change in these parameters or a shortening of
the retrograde atrial or accessory pathway refractory period.
Finally, the occurrence during ATP test in four patients of
AVRE or AVRT triggered by atrial extrasystoles empha-
sizes the importance in performing such testing prior to the
placement of the catheters in the cardiac chambers so as to
avoid catheter-induced extrasystoles.
Dual AV node pathways and AVRT. Dual AV node
pathways were found in 8% to 40% of patients with APs
undergoing electrophysiologic studies (8). The incidence of
9/33 (27%) patients observed in our study is consistent with
the results contained in the literature. More importantly, we
found that the administration of ATP at the dose that
resulted in any of the study end points (AVRE or AVRT)
allowed the noninvasive diagnosis of dual AV node physi-
ology in seven (78%) of these nine patients.
Another interesting observation in our patients with dual
AV node physiology is that none of them exhibited AV
nodal echo beats, likely reflecting the lack of conduction in
the retrograde fast pathway. It is tempting to speculate that
the occurrence of AV nodal echo beats in any of these
Figure 3. Patient 24. Initiation of AV reentrant echo beats following the administration of 30 mg ATP in a patient with a concealed posteroseptal AP and
no electrophysiologic evidence of dual AV node physiology. One echo beat occurs after each of four consecutive sinus beats (QRS complexes No. 2 through
No. 5) with the first echo following a slight prolongation (20 ms) in PR interval. A sinus beat associated with a shorter PR interval subsequently occurs,
followed by an atrial premature beat and another AV reentrant echo beat.
808 Belhassen et al. JACC Vol. 36, No. 3, 2000
Diagnosis of Concealed Accessory Pathway With ATP September 2000:803–10
patients would have prevented the occurrence of AVRE/
AVRT and thereby the diagnosis of concealed AP.
Study limitations. The main goal of the present study was
to assess the use of ATP in the diagnosis of concealed AP
and secondarily to determine the incidence of dual AV node
physiology in patients with AVRT. Therefore, one cannot
exclude that the incidence of dual AV node physiology
would have been even greater had higher doses of ATP been
tested in those patients who developed AVRE or AVRT
associated with a slight PR prolongation.
Although it is impossible to exclude that the first ob-
served AVRE beats were in fact atrial premature beats,
several findings in our study made this possibility unlikely:
1) in 19 of 21 patients, the first AVRE beats followed a
slight (,50 ms, n 5 13) or marked ($50 ms, n 5 6)
prolongation of PR interval, suggesting that a critical AV
nodal delay was required to allow the occurrence of these
beats strongly supporting a AV reentrant mechanism; in
only one patient was the first AVRE triggered by an atrial
extrasystole; 2) by study design, the morphology of the
P wave and its relationship with the preceding QRS
complex were identical to that present during AVRT
induced at electrophysiologic study; that would be a rather
coincidental finding for a premature atrial beat; 3) no atrial
premature beat occurred in the nine patients who had a
repeat ATP test after radiofrequency ablation of their APs
and exhibited AVRE beats at baseline ATP test; in the only
patient (no. 33) in whom such event was suspected, subse-
quent electrophysiologic study suggested that this “atrial
extrasystole” was likely an AVRE involving a second acces-
sory pathway; and 4) no atrial ectopic beat was observed
during ATP test in any of our 27 control group patients.
Clinical implications. Results of the present study show
that the diagnosis of concealed AP can be suspected using
the ATP test in 73% of patients with AVRT. In addition,
the safety of the test suggests it could be used as a bedside
test. Taking into account our previous results showing that
the diagnosis of dual AV node physiology can be suspected
by ATP test in 76% of patients with AVNRT (2), as well as
the fact that AVNRT and AVRT together represent 85% of
all cases of PSVT in patients without antegradely conduct-
ing AP (1), it is likely that ATP (or adenosine) testing could
be helpful in the noninvasive diagnosis of the mechanism of
PSVT in about two-thirds of patients with PSVT and no
Figure 4. Patient 27. (A) Induction of a sustained AV reentrant tachycardia following the administration of 10 mg ATP in a patient with a concealed left
free wall AP. About 10 s after the ATP bolus, tachycardia is initiated during stable sinus rhythm (cycle length 540 ms). Note a slight and progressive
prolongation in PR interval preceding the tachycardia initiation. The right bundle branch block present is catheter-induced. (B) After radiofrequency
ablation of the AP, no tachycardia is induced 10 s after administration of the same dose of ATP and achievement of sinus cycle length and PR interval
similar to baseline.
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ventricular preexcitation. Studies are being completed in our
laboratories that evaluate the predictive accuracy of ATP
test for identifying patients with palpitations or PSVT of
unclear mechanism who are likely to benefit from invasive
electrophysiologic evaluation. Further studies are required
to assess the potential use of the ATP test in the noninvasive
identification of other types of tachyarrhythmias, such as
atrial fibrillation, taking into account the well-known fibril-
latory effects of adenosine compounds at the atrial level (9).
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